{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-000500","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.987507+00:00","generated_at":"2026-06-20T01:52:59.366148+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PharmaCyte Biotech authorizes new $10M share repurchase program","bullets":["Board authorized repurchase of up to $10M of common stock, effective immediately for two years.","Prior program (June 2022) repurchased ~3.41M shares for ~$9.3M as of filing date.","Program will be funded from available cash; CEO cites strong balance sheet and shareholder commitment.","Company continues evaluating internal programs and exploring strategic opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-000500","json":"https://secwatch.observer/filing/0001683168-23-000500.json","markdown":"https://secwatch.observer/filing/0001683168-23-000500.md","text":"https://secwatch.observer/filing/0001683168-23-000500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823000500/0001683168-23-000500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823000500/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:52:59.366148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}